Abstract：
Chromosomal aberrations are a common feature of cancer and can fuel cancer progression and treatment resistance. In chronic lymphocytic leukemia (CLL), the presence of multiple chromosomal aberrations is commonly referred to as \"genomic complexity\" or \"complex karyotype\"- (CKT). In the context of chemo- and chemoimmunotherapy, genomic complexity is associated with poor response to treatment and short survival, while some targeted therapies are able to mitigate its adverse prognostic impact. This article reviews currently available data and literature on the role of genomic complexity in CLL. The currently established tools to measure genomic complexity in patients with CLL are summarized and their strengths and weaknesses for routine diagnostics are evaluated. Moreover, possible definitions of CKT as an indicator for genomic complexity are discussed. Finally, data on the impact of CKT on clinical outcomes of patients with CLL are reviewed and the implications for patient stratification are presented.
摘要：
染色体畸变是癌症的常见特征，可以促进癌症进展和治疗抵抗。在慢性淋巴细胞白血病（CLL）中，多重染色体畸变的存在通常被称为“基因组复杂性”或“复杂核型”-(CKT)。在化学和化学免疫疗法的背景下，基因组复杂性与治疗反应差和生存期短有关，而一些靶向治疗能够减轻其不良预后影响。本文回顾了关于基因组复杂性在CLL中的作用的现有数据和文献。总结了目前建立的测量CLL患者基因组复杂性的工具，并评估了它们在常规诊断中的优缺点。此外，讨论了CKT作为基因组复杂性指标的可能定义。最后,我们对CKT对CLL患者临床结局影响的相关数据进行了综述,并介绍了对患者分层的影响.
